Literature DB >> 18208765

Indirect effects of cytomegalovirus infection in solid organ transplant recipients.

María José Pérez-Sola1, Juan José Castón, Rafael Solana, Antonio Rivero, Julián Torre-Cisneros.   

Abstract

Cytomegalovirus (CMV) infection is an important and frequent complication in solid organ transplant (SOT) recipients. This infection causes direct effects by viral inclusion in the cells of various tissues, as well as indirect effects by interaction between low levels of viremia and the host immune response. These indirect effects, such as increased incidence of graft rejection and opportunistic infections or decreased recipient survival, can be as severe as the direct effects, and thus require implementation of preventative practice guidelines. Universal prophylaxis against CMV has shown to be effective for preventing CMV disease and asymptomatic CMV replication, and can be considered the treatment of choice for preventing the indirect effects of this infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18208765     DOI: 10.1157/13114394

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  9 in total

1.  Simultaneous monitoring of cytomegalovirus-specific antibody and T-cell levels in seropositive heart transplant recipients.

Authors:  Javier Carbone; Nallibe Lanio; Antonio Gallego; Florian Kern; Joaquin Navarro; Patricia Muñoz; Roberto Alonso; Pilar Catalán; Juan Fernández-Yáñez; Jesús Palomo; Manuel Ruiz; Eduardo Fernández-Cruz; Elizabeth Sarmiento
Journal:  J Clin Immunol       Date:  2012-02-29       Impact factor: 8.317

2.  Age-dependent association between low frequency of CD27/CD28 expression on pp65 CD8+ T cells and cytomegalovirus replication after transplantation.

Authors:  Sara Cantisán; Julián Torre-Cisneros; Rosario Lara; Alberto Rodríguez-Benot; Francisco Santos; Juan Gutiérrez-Aroca; Inmaculada Gayoso; Marcelino González-Padilla; Manuel Casal; Antonio Rivero; Rafael Solana
Journal:  Clin Vaccine Immunol       Date:  2009-08-05

3.  Early renal function trajectories, cytomegalovirus serostatus and long-term graft outcomes in kidney transplant recipients.

Authors:  Jonathan P Law; Richard Borrows; David McNulty; Adnan Sharif; Charles J Ferro
Journal:  BMC Nephrol       Date:  2021-03-20       Impact factor: 2.388

4.  Anti-CMV-IgG positivity of donors is beneficial for alloHSCT recipients with respect to the better short-term immunological recovery and high level of CD4+CD25high lymphocytes.

Authors:  Emilia Jaskula; Dorota Dlubek; Agnieszka Tarnowska; Janusz Lange; Monika Mordak-Domagala; Krzysztof Suchnicki; Mariola Sedzimirska; Agata Borowik; Sylwia Mizia; Andrzej Lange
Journal:  Viruses       Date:  2015-03-23       Impact factor: 5.048

Review 5.  The impact of cytomegalovirus infection on new-onset diabetes mellitus after kidney transplantation: a review on current findings.

Authors:  Behzad Einollahi; Mohsen Motalebi; Mahmood Salesi; Mehrdad Ebrahimi; Mehrdad Taghipour
Journal:  J Nephropathol       Date:  2014-10-01

Review 6.  [Effects of viral infection on transplant recipients].

Authors:  Juan José Castón; José Miguel Cisneros; Julián Torre-Cisneros
Journal:  Enferm Infecc Microbiol Clin       Date:  2007-10       Impact factor: 1.731

Review 7.  [Role of viral infections in immunosuppressed patients].

Authors:  M Salavert; R Granada; A Díaz; R Zaragoza
Journal:  Med Intensiva       Date:  2011-02-15       Impact factor: 2.491

8.  Clinical features of BK-polyomavirus and cytomegalovirus co-infection after kidney transplantation.

Authors:  Ulrich Jehn; Katharina Schütte-Nütgen; Joachim Bautz; Hermann Pavenstädt; Barbara Suwelack; Gerold Thölking; Stefan Reuter
Journal:  Sci Rep       Date:  2020-12-29       Impact factor: 4.379

9.  A mouse model of interstitial pneumonitis induced by murine cytomegalovirus infection after allogeneic skin transplantation.

Authors:  Dequn Ni; Haiyang Yu; Wei Zhang; Lin Gan; Jiqiang Zhao; Mingli Wang; Jason Chen
Journal:  Biomed Res Int       Date:  2013-07-02       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.